Sarepta skips over a Duchenne patent battle with $35M settlement
Cambridge-based Sarepta Therapeutics has agreed to pay $35 million plus royalties and potential milestones to a California biotech to resolve a dispute over patents on its Duchenne muscular dystrophy drug.
Sarepta (Nasdaq: SRPT) said Tuesday that it had reached an agreement to license the intellectual property of San Rafael-based BioMarin Pharmaceutical (Nasdaq: BMRN). BioMarin had previously challenged key patents covering Sarepta’s approved Duchenne drug, Exondys 51, as well as other so-called…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
More News: Biotechnology | Health Management | Muscular Dystrophy | Pharmaceuticals | Reflex Sympathetic Dystrophy